Hikma Pharmaceuticals PLC (LON:HIK)
1,594.00
+4.00 (0.25%)
At close: Dec 5, 2025
Hikma Pharmaceuticals Revenue
Hikma Pharmaceuticals had revenue of $1.66B USD in the half year ending June 30, 2025, with 16.19% growth. This brings the company's revenue in the last twelve months to $3.22B, up 6.60% year-over-year. In the year 2024, Hikma Pharmaceuticals had annual revenue of $3.13B with 8.77% growth.
Revenue (ttm)
$3.22B
Revenue Growth
+6.60%
P/S Ratio
1.50
Revenue / Employee
$338.53K
Employees
9,500
Market Cap
3.53B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.13B | 252.00M | 8.77% |
| Dec 31, 2023 | 2.88B | 358.00M | 14.22% |
| Dec 31, 2022 | 2.52B | -36.00M | -1.41% |
| Dec 31, 2021 | 2.55B | 212.00M | 9.06% |
| Dec 31, 2020 | 2.34B | 134.00M | 6.07% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Convatec Group | 1.72B |
| HUTCHMED (China) | 439.54M |
| Genus | 672.80M |
| Oxford Nanopore Technologies | 204.69M |
Hikma Pharmaceuticals News
- 27 days ago - Hikma Pharmaceuticals PLC (HKMPY) Shareholder/Analyst Call Transcript - Seeking Alpha
- 2 months ago - FTSE 100 hits another high despite concerns over US government shutdown - Evening Standard
- 4 months ago - Hikma Pharmaceuticals PLC (HKMPF) Q2 2025 Pre Recorded Earnings Call Transcript - Seeking Alpha
- 4 months ago - Hikma Pharmaceuticals PLC 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 4 months ago - Hikma Pharmaceuticals PLC (HKMPF) Q2 2025 Q&A Earnings Call Transcript - Seeking Alpha
- 4 months ago - Hikma Pharmaceuticals tumbles after injectables margin outlook cut - Reuters
- 4 months ago - Hikma Pharmaceuticals: a quality compounder waiting for a catalyst - The Armchair Trader
- 5 months ago - Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US - PRNewsWire